Abstracts tagged "outcome measures and patient-reported outcome measures"

Abstract Number: 350 • 2017 ACR/ARHP Annual Meeting
Patients with Gout Consider Zero Flares over the Previous Six or Twelve Months Necessary for a Remission State
William J. Taylor¹, Nicola Dalbeth², Kenneth Saag³, Jasvinder A. Singh⁴, Elizabeth J. Rahn⁵, Amy S. Mudano⁶, Yi-Hsing Chen⁷, Ching-Tsai Lin⁸, Paul Tan², Worawit Louthrenoo⁹, Janitzia Vazquez-Mellado¹⁰, Hansel Hernández-Llinas¹¹, Tuhina Neogi¹², Ana Beatriz Vargas-Santos¹², Geraldo Castelar-Pinheiro¹³, Rodrigo B. Chaves-Amorim¹³, Till Uhlig¹⁴, Hilde B Hammer¹⁴, Maxim Eliseev¹⁵, Fernando Perez-Ruiz¹⁶, Lorenzo Cavagna¹⁷, Geraldine M. McCarthy¹⁸, Lisa K. Stamp¹⁹, Martijin Gerritsen²⁰, Viktoria Fana²¹, Francisca Sivera²² and Angelo L. Gaffo⁵, ¹University of Otago, Wellington, New Zealand, ²University of Auckland, Auckland, New Zealand, ³Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Taichung Veterans General Hospital, Taichung, Taiwan, ⁸Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, ⁹Div of Rheumatology, Dept of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, ¹⁰Rheumatology, Hospital General de Mexico, Mexico City, Mexico, ¹¹Hospital General de Mexico, Mexico City, Mexico, ¹²Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ¹³Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, Brazil, ¹⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁵V. A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation, ¹⁶Servicio de Reumatología, Vizcaya, Spain, ¹⁷Division of Rheumatology, University and IRCCS Policlinico S. Matteo, Pavia, Italy, ¹⁸Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ¹⁹University of Otago, Christchurch, New Zealand, ²⁰Westfries Gasthuis, Hoorn, Netherlands, ²¹Center for Rheumatology and Spine Diseases, Rigshospitalet , Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ²²Sección de Reumatología, Hospital General Universitario de Elda., Elda, Spain
Background/Purpose: Treatment targets for gout generally focus on serum urate, but patient-centred targets may be equally important. We seek to determine the relationship between gout…
Abstract Number: 357 • 2017 ACR/ARHP Annual Meeting
Determinants of Patient and Physician Disagreement on Presence of a Gout Flare
Aprajita Jagpal¹, Nicola Dalbeth², William J. Taylor³, Kenneth Saag¹, Jasvinder A. Singh⁴, Amy S. Mudano⁵, Elizabeth J. Rahn⁶ and Angelo L. Gaffo⁶, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Auckland, Auckland, New Zealand, ³University of Otago, Wellington, New Zealand, ⁴Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Flare is a central feature of gout and patient self-report of flare was found to be an important element in a gout flare definition…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].